A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

PURPOSE: BRAF V600E mutant metastatic colorectal cancer represents a significant clinical problem, with combination approaches being developed clinically with oral BRAF inhibitors combined with EGFR-targeting antibodies. While compelling preclinical data have highlighted the effectiveness of combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Lavinia, Tran, Ben, Tie, Jeanne, Markman, Ben, Ananda, Sumi, Tebbutt, Niall C., Michael, Michael, Link, Emma, Wong, Stephen Q., Chandrashekar, Sushma, Guinto, Jerick, Ritchie, David, Koldej, Rachel, Solomon, Benjamin J., McArthur, Grant A., Hicks, Rodney J., Gibbs, Peter, Dawson, Sarah-Jane, Desai, Jayesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011885/
https://www.ncbi.nlm.nih.gov/pubmed/36638198
http://dx.doi.org/10.1158/1078-0432.CCR-22-3094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011885/
https://www.ncbi.nlm.nih.gov/pubmed/36638198
http://dx.doi.org/10.1158/1078-0432.CCR-22-3094

Ejemplares similares